Relationship between blood-interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; A pilot study

Akemi Tokutsu  
University of Occupational and Environmental Health, Japan  https://orcid.org/0000-0002-8035-5551

Yosuke Okada  
University of Occupational and Environmental Health, Japan

Keiichi Torimoto  
University of Occupational and Environmental Health, Japan

Yoshiya Tanaka  (tanaka@med.uoeh-u.ac.jp)

Research

Keywords: Ambulatory Glucose Profile (AGP), Flash Glucose Monitoring (FGM), Inter-quartile Range (IQR), retrospective study

DOI: https://doi.org/10.21203/rs.3.rs-35230/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Treatment indexes using continuous glucose monitoring (CGM) have become standardized internationally, and the use of ambulatory glucose profile (AGP) is currently recommended. However, the relationship between AGP indexes and standardized CGM metrics has not been investigated. Using flash glucose monitoring (FGM), this retrospective study served to evaluate the association of the inter-quartile range (IQR) of AGP with standardized CGM metrics. Methods The study subjects were 30 patients with type 2 diabetes mellitus (T2DM) and 23 non-diabetic patients (control group). We evaluated average IQR (AIQR) and standardized CGM metrics. The primary endpoint was the relationship between AIQR and Time in range (TIR) in a 24-hour period. Results In the T2DM group, the AIQR was notably high and correlated negatively with TIR, and positively with Time above range, average interstitial glucose level, standard deviation of interstitial glucose, coefficient of variation of interstitial glucose, and mean of daily difference in blood glucose (MODD). For the T2DM group, the AIQR was notably lower in patients who achieved TIR>70%, compared to those who did not. The AIQR cutoff value, as determined by ROC analysis, was 28.3 mg/dL for those who achieved TIR>70%. No association was detected between the presence of hypoglycemia and AIQR. Conclusions Our study is the first to provide the AIQR cutoff value for achieving the TIR target value. The range of interstitial glucose variability in AGP was associated with indexes of intra- and interday variations and hyperglycemia. Our results provide new perspectives in the yet-to-be established methods for evaluation of AGP in practical clinical settings.

Background

Continuous glucose monitoring (CGM) and flash glucose monitoring (FGM) are becoming standard devices used for management of glucose levels in diabetic patients. A consensus report on CGM metrics was published for the first time last year, and the time-in-range (TIR) and blood glucose levels of ≥180 and <70 mg/dl have become international standards as diabetes treatment indexes. A study using DCCT research data indicated that TIR correlates with retinopathy and nephropathy, while the percentage of low blood glucose under 70 is associated with the risk of serious hypoglycemia.

On the other hand, the use of the ambulatory glucose profile (AGP) as a standard CGM report has been recommended. The AGP proposed by Mazze et al. is an analytical method that allows easy and visual understanding of various factors, such as the time during the day when there is a high probability of development of hypoglycemia or hyperglycemia, and times during the day with large swings in interstitial glucose levels; the AGP can also indicate movements and trends in interstitial glucose variability (Supplemental Figure 1). Although indexes, such as the inter-quartile range (IQR), inter-decile range (IDR) and median are the leading AGP indicators, their relationships with the existing standardized CGM metrics have not been identified; furthermore, the target values and cutoff values in T2DM have not been proposed.

In this pilot study, we used FGM and evaluated the inter-quartile range (IQR) of AGP and its association with standardized CGM metrics. We also examined the target values and cutoff values in T2DM.
Materials And Methods

Subjects

We conducted a retrospective study that included 30 patients with type 2 diabetes mellitus (T2DM) and 23 non-diabetic patients who attended the outpatient clinic of the University of Occupational Medicine Hospital and University of Occupational Medicine Wakamatsu Hospital, between September 2018 to January 2019. At the time of the study, the T2DM patients were being treated for T2DM and monitored with the flash glucose monitoring system (FGMS® System FreeStyle Libre Pro System, Abbott Diabetes Care, Inc.) for at least eight days. The following inclusion criteria were applied in the selection of the T2DM group: 1) Patients aged between 30-80 years at the time of consent to the study; 2) Outpatients with T2DM, who were examined clinically by diabetologists and tested for GAD antibodies as well as other tests to exclude type 1 diabetes and latent adult-onset autoimmune diabetes (LADA); 3) Patients who had not changed (added, switched, or discontinued) their glucose-lowering medications or changed the doses of these medications within four weeks before the start date of monitoring with the FreeStyle Libre Pro sensor. We also applied the following exclusion criteria: 1) Type 1 or secondary diabetes mellitus; 2) Patients with severe infections or serious trauma, and pre- and postoperative patients; 3) Patients on dialysis; 4) Patients with severe liver dysfunction (AST 100 IU/l or greater); 5) Patients with moderate or serious heart failure (NYHA/New York Heart Association Classification III or higher stage); 6) Pregnant, lactating, or planning to become pregnant patients.

Patients and hospital staff confirmed to be non-diabetic and had no glucose intolerance were recruited as the non-diabetic control group.

The study protocol and opt-out method of informed consent were approved by the ethics committee of the University of Occupational and Environmental Health (Trial registration: H27-186, Registered 25 Dec 2015).

We used the following baseline definition of diabetic microangiopathy: The earliest clinical evidence of nephropathy is the appearance of low but abnormal levels ($\geq 30$ mg/day or $20 \mu g/min$) of albumin in the urine, referred to as microalbuminuria. The urinary albumin excretion rate is presented as the albumin-to-creatinine ratio (mg/g creatinine).

In this study, the albumin-to-creatinine ratio was measured in single voided urine samples and microalbuminuria was defined as 30-300 mg/g creatinine. Diabetic retinopathy was defined as simple or more severe retinopathy based on funduscopic examination by ophthalmologists. Diabetic neuropathy was diagnosed by the presence of two or more clinical symptoms (e.g., bilateral spontaneous pain, hyposthesia, paresthesia of the legs), absence of ankle tendon reflexes, and decreased vibration sensations using a C128 tuning fork.

Flash glucose monitoring system
The device automatically measures glucose concentration in the interstitials every 15 minutes and records the interstitial glucose level 96 times a day. The calculation can be performed using the instructions provided by Microsoft® (Redmond, WA) Excel and the EasyGV (available free for non-commercial use at www.easygv.co.uk) The average interstitial glucose level (AG), median, standard deviation (SD), coefficient of variation (CV), percent time at interstitial glucose level of 70-180 mg/dl (TIR; time-in-range), percent time with interstitial glucose level at >180 mg/dl (TAR; time-above-range), percent time with interstitial glucose level at <70 mg/dl (TBR; time-below-range), maximum, minimum, glucose management indicator (GMI, new terms used for estimating HbA1c from CGM)\(^6\), mean of daily difference in blood glucose (MODD), low blood glucose index (LBGI), high blood glucose index (HBGI), and AGP 25-75th percentile width (IQR; interquartile range) were obtained from the data recorded with the FGM\(^7,8\).

Hypoglycemia was defined as interstitial glucose value <70 mg/dl, as measured by FGM. The FGM recorded and stored interstitial glucose levels over seven consecutive days. Data collected over the first day were discarded to avoid bias due to the insertion and removal of FGM, or insufficient stability of the monitoring system. We recorded the daily average value, and listed the average value of seven days.

**Laboratory tests**

HbA1c (%) was measured by HPLC using Tosoh HLC-723 G8 (Tosoh Co., Kyoto, Japan), and recorded as a NGSP (National Glycohemoglobin Standardization Program) value. eGFR (estimated glomerular filtration rate) was calculated as \(194 \times \text{serum creatinine concentration (mg/dl)} - 1.094 \times \text{age} - 0.287\) in men, and \(194 \times \text{serum creatinine concentration (mg/dl)} - 1.094 \times \text{age} - 0.287 \times 0.739\) in women.

**Statistical analysis**

Data are shown as mean±standard deviation. The Shapiro-Wilk normality test was used to check the distribution of data. Differences between the mean values of various parameters in two groups were tested for statistical significance using the Student's t-test after confirming equal variance by the F test and Welch's t-test, or the presence of normal distribution. The Mann-Whitney U test was used for data with skewed distribution, and Spearman's correlation analysis was used for relationships between two variables. We also analyzed the cutoff values using the Receiver Operating Characteristic (ROC) curve. The required sample size in ROC analysis was calculated as 25 patients in total using an area under the curve (AUC) of 0.85, test power of 0.80, significance level of 5%, and a 5:1 ratio for the group that achieved TIR >70% versus the group that did not achieve TIR>70%. A \(p\) value <0.05 denoted the presence of statistical significance. All statistical procedures were performed using the SPSS Statistical software version 25.0 (SPSS Inc., Chicago, IL).

**Results**

**Clinical characteristics of study participants**

None of the patients reported sensor-related problems, such as skin peeling and skin irritation, to warrant dropout/withdrawal from the study. Table 1 lists the clinical characteristics of the study subjects. They
comprised 53 subjects (22 males, 31 females). Of these, 23 formed the non-diabetic control group (5 males and 18 females), with a mean age of 43.5±16.5 years (range, 19-88) and BMI of 22.0±3.3 kg/m². The diabetic group consisted of 30 patients (17 males, 13 females) with a mean age of 68.5±7.4 years (range, 51-79) and BMI of 24.1±3.9 kg/m², HbA1c of 6.7±0.6% (range, 5.7-7.7), and disease duration of 14.7±11.5 years (range, 1.3-43.0). For the diabetic group, 70% of the patients were using DPP-4 inhibitors and 50% were on biguanides. Among the study group, 6 were insulin users, with 3 using the long-acting basal insulin only, 1 using a mixture formulation of long-acting basal insulin and rapid-acting bolus insulin, and 2 using intensive insulin therapy.

Comparison of the diabetic and control groups

The FGM data of the diabetic group and control group are shown in Supplemental Table. The average IQR (AIQR) was 17.3±4.3 mg/dl for the control group, and significantly higher for the diabetic group (30.1±11.7 mg/dl, p<0.001). The TBR/TIR/TAR were 2.7±5.3/96.1±5.5/1.3±2.1% in the control group and 1.6±2.4/85.8±12.8/12.6±12.5% in the diabetes group. The TIR was significantly lower (p<0.001), while TAR was significantly higher (p<0.001) in the diabetic group. There were no notable differences between the two groups with respect to the minimum, TBR, and LBGI.

Correlation between AIQR and CGM index in the diabetic group

Table 2 summarizes the results of analysis of the correlation between AIQR and CGM metrics in the diabetic group. The AIQR correlated negatively (r=-0.840, p<0.001, Figure 1) with TIR, and positively with maximum, SD, CV, MODD, HGBI, and TAR (p<0.001, each). However, there was no correlation between AIQR and the hypoglycemia indexes of minimum, LBGI, and TBR. Analysis of the data of all 20 patients with hypoglycemia showed a significant correlation between AIQR and TBR (p=0.032, r=0.481).

Comparison of AIQR according to TIR achievement in the diabetic group

We compared the AIQR of the diabetic group based on the achievement of TIR>70% and TIR>90% (Table 3). The analysis showed 25 patients achieved TIR>70% and 5 patients that did not, while 14 patients achieved TIR>90% and 16 did not. The AIQR of the group that achieved TIR>70% was significantly lower (27.6±9.1 mg/dL) than that of the group that did not (42.2±16.3 mg/dL, p=0.017). Similarly, the AIQR of the group that achieved TIR>90% was significantly lower (22.6±4.8 mg/dL) than that of the group that did not (36.7±12.6 mg/dL, p<0.001).

To evaluate the AIQR cutoff values for the groups that achieved TIR>70% and TIR>90%, ROC curves were generated and the areas under the curves (AUC) were computed. ROC curve analysis showed an AIQR cutoff value of 28.3 mg/dL (AUC=0.848, 95%CI 0.621-0.950) for the group that achieved TIR>70%, and 22.9 mg/dL (AUC=0.929, 95%CI 0.778-0.980) for the group that achieved TIR>90% (Supplemental Figure 2).
Next, we used an AIQR of 28.3 mg/dL as the cutoff value and compared the data with TIR. The TIR was 94.1±4.3% in the AIQR<28.3 mg/dL group and 76.4±12.7% (p<0.001) in the AIQR ≥28.3 mg/dL group. On the other hand, using an AIQR of 22.9 mg/dL as the cutoff value, the TIR were 97.0±2.6% and 82.4±12.7% (p=0.001) for the AIQR<22.9 and ≥22.9 mg/dL groups, respectively (Figure 2).

Comparison of the hypoglycemia and non-hypoglycemia subgroups

Table 4 shows the results of comparison of CGM metrics in the presence of hypoglycemia. Hypoglycemia was noted in 20 of the 30 patients of the diabetic group, and the hypoglycemia indexes of TBR and LGBI were significantly higher in the hypoglycemia group than the non-hypoglycemia group (p<0.001, each). However, there was no notable difference in AIQR in the presence of hypoglycemia. AG, GMI, and TAR were all significantly higher in the non-hypoglycemia group (p=0.005, p=0.005, p=0.037).

Discussion

The major findings of the present study using the FGM were the following: 1) AIQR correlated negatively with TIR, 2) the higher the TIR lower the variability seen by the AGP, 3) AIQR correlated positively with SD, CV, and MODD, and 4) Lack of relationship between AIQR and hypoglycemia.

Our study also established the AIQR cutoff values for achieving the TIR target values. AGP is an excellent tool that clearly and visually presents the trends in interstitial glucose variability for the individual patient; our study showed that AIQR is a valuable index for use in AGP.

Our data showed that AIQR correlates negatively with TIR, and that the longer the time interstitial glucose is maintained within the range of 70 to 180 mg/dL, the smaller the variation range in AGP. TIR refers to the percent time during the 24-hour period when blood glucose is within the range of 70-180 mg/dL. TIR provides a more complete picture of blood glucose than HbA1c, and hence makes it possible to offer personalized treatment options. Similar to HbA1c, TIR is reported to correlate strongly with the risk of retinopathy and/or onset of microalbuminuria. Other studies found that TIR is independent of HbA1c and that it is associated with cardiovascular autonomic neuropathy. Furthermore, TIR correlates strongly with HbA1c, and was recently recommended by the American Diabetes Association (ADA) for use along with HbA1c for targeted blood glucose control.

IQR is in the 25-75th percentile range on the AGP, and is an excellent visual indicator of interstitial glucose variability; although there is no reported relationship between IQR and standardized CGM metrics. To our knowledge, our study is the first to define the AIQR-TIR relationship. Importantly, setting the cutoff values for AIQR makes it easier to evaluate treatment goals especially achieving the TIR targets. Following ADA's target of TIR>70% in T2DM patients, we established the AIQR cutoff values of 28.3 mg/dL for TIR>70% and 22.9 mg/dL for a stricter adherence to TIR>90%. These indexes are useful markers to use when setting target treatment values using the AGP. These parameters are useful as visual indicator to highlight the therapeutic target with the patients.
The IQR has also been discussed as a marker of interday variations\textsuperscript{15}. Another strong aspect of our study was the strong correlation between AIQR and the SD and CV (which are markers of intraday variations), in addition to the correlation between AIQR and MODD (which is a marker of interday variation). In this regard, Monnier et al.\textsuperscript{16} proposed the use of indexes that can evaluate blood glucose variability in addition to chronic hyperglycemia and hypoglycemia, as a strategy for monitoring blood glucose to inhibit progression of cardiovascular disorders. The results of the present study suggest that IQR is useful index for evaluation of intra- and interday variations in interstitial glucose levels. In practical clinical settings from hereon, a large IQR will require analysis of the factors behind interday variations, as well as necessitate evaluation of the factors responsible for intraday variations, including, for example, postprandial glucose and low blood glucose levels.

Our analysis showed the lack of any association between AIQR and presence of hypoglycemia, and that low interstitial glucose is associated with AG and LBGI. These results suggest that AIQR is not suitable for use to predict the extent of hypoglycemia; and thus, we advise instead to visually evaluate each case when assessing low interstitial glucose in AGP. It is noteworthy that a number of investigators found close associations between low blood glucose and certain markers, such as AG and LBGI\textsuperscript{17, 18}, similar to our findings. Therefore, AG, CV, LBGI and other CGM metrics can also be used with other indexes to evaluate objectively the risk of hypoglycemia in clinical settings.

There were following limitations in this study. The FGMS® System FreeStyle Libre Pro System can measure up to 14 consecutive days. However, recent studies have reported that measurements taken on day 1 and those after day 12 are inaccurate\textsuperscript{19}. Based on this limitation of the system, we decided to use the data of only day 2 to day 8 (7 days), excluding the data of day 1, in our analysis. Since The International Consensus Statement recommends AGP analysis of the data of 14 days\textsuperscript{20}, further studies are necessary to verify whether the results of 7-day analysis are identical to those of 14 days. In addition, we did not record interstitial glucose density of $\geq 500$ mg/dL based on the use of FGM, and accordingly, or study did not include patients with poor blood glucose control. This is an important limitation to mention here because the results for such patients may be different from those obtained in the present study. And furthermore, this research work was a cross-sectional study conducted at two facilities with only a relatively small number of patients. Therefore, it was not possible to analyze this subject according to hypoglycemia or medication type. To substantiate the results of this study, a multi-center study of a large number of cases needs to be performed.

**Conclusion**

This study noted, for the first time, a strong correlation between TIR and interstitial glucose variability range that can be understood visually using the AGP. The study also provided the AIQR cutoff values for achieving TIR target values. Furthermore, the interstitial glucose variability range in AGP was strongly associated with indexes of intra- and interday variations; though there was no association with LBGI. Our results may provide new perspectives in the yet-to-be established methods for evaluating AGP in practical clinical settings.
Abbreviations

CGM, continuous glucose monitoring;
AGP, ambulatory glucose profile;
FGM, flash glucose monitoring;
IQR, inter-quartile range;
T2DM, type 2 diabetes mellitus;
average IQR, average inter-quartile range;
TIR, Time in range;
SD, standard deviation;
CV, coefficient of variation;
MODD, mean of daily difference of blood glucose;
ROC analysis, Receiver Operating Characteristic analysis;
IDR, inter-decile range;
AG, average interstitial glucose level;
TAR, time above range;
TBR, time below range;
GMI, glucose management indicator;
LBGI, low blood glucose index;
HBGI, high blood glucose index;
HbA1c, Hemoglobin A1c;
eGFR, estimated glomerular filtration rate;
AUC, area under the curve;
BMI, Body Mass Index;
DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor;
95%CI, 95% Confidence Interval;

**Declarations**

*Ethics approval and consent to participate*

The study protocol and opt-out method of informed consent were approved by the ethics committee of the University of Occupational and Environmental Health (Trial registration: H27-186, Registered 25 Dec 2015).

*Consent for publication*

Not applicable.

*Availability of data and materials*

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

*Competing interests*

The authors declare that they have no competing interests.

*Funding*

No funding was received for this study from public, commercial, or non-for-profit entities.

*Authors’ contributions*

AT collected the data. KT and AT analyzed the data. AT wrote the manuscript. YO and KT designed the study and reviewed the manuscript. YT reviewed the manuscript.

All authors read and approved the final manuscript.

*Acknowledgements*

Not applicable.

**References**

1. Danne T, Nimri R, Battelino T, et al.: International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40: 1631-1640.

2. Beck RW, Bergenstal RM, Riddlesworth TD, et al.: Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019; 42: 400-05.
3. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C.: The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: Analysis of the DCCT data set. Diabetes Technol Ther 2019; 21: 1-5.

4. Mazze RS, Lucido D, Langer O, Hartmann K, Rodbard D.: Ambulatory glucose profile: Representation of verified self-monitored blood glucose data. Diabetes Care 1987; 10: 111-7.

5. Molitch ME, DeFronzo RA, Franz MJ, et al.: Nephropathy in diabetes. Diabetes Care 2004; 27(suppl 1): s79-83.

6. Bergenstal RM, Beck RW, Close KL, et al.: Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018; 41: 2275–2280.

7. Molnar GD, Taylor WF, Ho MM: Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instability. Diabetologia 1972; 8: 342–348.

8. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W.: Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 1997; 20: 1655–1658.

9. Bergenstal RM, Ahmann AJ, Bailey T, et al.: Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013; 15: 198-211.

10. Beyond A1C Writing Group.: Need for regulatory change to incorporate beyond A1C glycemic metrics. Diabetes Care 2018; 41: e92-e94.

11. Guo Q, Zang P, Xu S, et al.: Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabetes Res 2020; 5817074.

12. Vigersky RA, McMahon C: The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther 2019; 21: 81-85.

13. Matthaei S: Assessing the value of the ambulatory glucose profile in clinical practice. Br J Diab 2014; 14: 148-152.

14. Rodbard D: Interpretation of continuous glucose monitoring data: Glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009; 11(Suppl 1): s55-67.

15. Bergenstal RM, Ahmann AJ, Bailey T, et al.: Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The ambulatory glucose profile. J Diabetes Sci Technol 2013; 7: 562-78.

16. Monnier L, Colette C, Owens DR: The application of simple metrics in the assessment of glycaemic variability. Diabetes Metab 2018; 44: 313-319.

17. Torimoto K, Okada Y, Hajime M, Kenichi T, Yoshiya T: Risk factors of hypoglycemia in patients with type 2 diabetes mellitus: A study based on continuous glucose monitoring. Diabetes Technol Ther 2018; 20:603-612.

18. Rodbard D: Metrics to evaluate quality of glycemic control: Comparison of time in target, hypoglycemic, and hyperglycemic ranges with “risk indices”. Diabetes Technol Ther 2018; 20: 325-
34.

19. Ajjan RA, Cummings MH, Jennings P, et al: Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice. Diab Vasc Dis Res 2018 May;15(3):175-184.

20. Battelino T, Danne T, Bergenstal RM, et al: Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42(8):1593-1603.

Tables

Table 1. Baseline characteristics of the 53 patients.
|                                | mean±SD         |
|--------------------------------|-----------------|
|                                | Control group (n=23) | Diabetic group (n=30) |
| Sex (male/female)              | 5/18            | 17/13               |
| Age (year)                     | 43.5±16.5       | 68.5±7.4            |
| Height (cm)                    | 165.2±11.3      | 160.7±8.4           |
| Weight (kg)                    | 60.9±15.0       | 62.6±13.4           |
| BMI (kg/m²)                    | 22.0±3.3        | 24.1±3.9            |
| SBP (mmHg)                     | 116.2±11.5      | 134.8±17.0          |
| DBP (mmHg)                     | 69.1±9.1        | 73.5±9.0            |
| Duration of diabetes (year)    |                 | 14.7±11.5           |
| HbA1c (%)                      |                 | 6.7±0.6             |
| Creatinine (mg/dL)             | 0.87±0.26       | 63.5±14.8           |
| eGFR (mL/min/1.73m²)           |                 |                     |
| Neuropathy, n (%)              | 8 (26.7)        |                     |
| Retinopathy, n (%)             | 3 (10.0)        |                     |
| Nephropathy, n (%)             | 6 (20.0)        |                     |
| Anti-diabetes treatment        |                 |                     |
| Diet only, n (%)               | 1 (3.0)         |                     |
| SU, n (%)                      | 0 (0)           |                     |
| Glinide, n (%)                 | 2 (6.7)         |                     |
| DPP-4 inhibitor, n (%)         | 21 (70.0)       |                     |
| Biguanide, n (%)               | 15 (50.0)       |                     |
| Thiazolidine, n (%)            | 5 (16.7)        |                     |
| SGLT-2 inhibitor, n (%)        | 7 (23.3)        |                     |
| α-glucose inhibitor, n (%)     | 7 (23.3)        |                     |
| GLP-1 receptor, n (%)          | 3 (10.0)        |                     |
| Insulin, n (%)                 | 6 (20.0)        |                     |

Sex, by c² test. Age, by Welch test. BMI: Body Mass Index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, eGFR: estimated glomerular filtration rate, SU: sulfonylureas, DPP-4 inhibitor: dipeptidyl
peptidase-4 inhibitor, SGLT-2 inhibitor: sodium-glucose transporter-2 inhibitor, GLP-1 receptor: Glucagon-like peptide-1 receptor.

Table 2. Correlation between average IQR and CGM index in the diabetic patients

|                      | correlation coefficient | p value |
|----------------------|-------------------------|---------|
| TIR                  | -0.840                  | <0.001  |
| AG                   | 0.805                   | <0.001  |
| Maximum              | 0.839                   | <0.001  |
| Minimum              | 0.181                   | 0.339   |
| SD                   | 0.822                   | <0.001  |
| CV                   | 0.512                   | 0.004   |
| MODD                 | 0.949                   | <0.001  |
| HBGI                 | 0.887                   | <0.001  |
| LBGI                 | 0.038                   | 0.844   |
| TAR                  | 0.868                   | <0.001  |
| TBR                  | 0.007                   | 0.970   |

P values by Spearman's rank correlation coefficient.

IQR, interquartile range: TIR, Time in range (70-180 mg/dL): AG, average interstitial glucose: SD, standard deviation: CV, coefficient of variation: MODD, mean of daily difference of blood glucose: HBGI, high blood glucose index: LBGI, low blood glucose index: TAR, Time above range (>180 mg/dL): TBR, Time below range (<70 mg/dl).

Table 3. Comparison of average IQR according to TIR achievement in diabetic patients.
### Average IQR by achieving TIR>70%

|                                | Achievement group (n=25) | non-Achievement group (n=5) | p value |
|--------------------------------|--------------------------|----------------------------|---------|
| Average IQR (mg/dL)            | 27.6±9.1                 | 42.2±16.3                  | 0.017   |

### Average IQR by achieving TIR>90%

|                                | Achievement group (n=14) | non-Achievement group (n=16) | p value |
|--------------------------------|--------------------------|-----------------------------|---------|
| Average IQR (mg/dL)            | 22.6±4.8                 | 36.7±12.6                   | <0.001  |

Data are mean±SD.

P values by Mann-Whitney test.

IQR, interquartile range: TIR, Time in range (70-180 mg/dL).

Table 4. Hypoglycemia versus non-Hypoglycemia in diabetic patients.

|                                | Hypoglycemia (n=20)      | non-Hypoglycemia (n=10)   | p value |
|--------------------------------|--------------------------|---------------------------|---------|
| AG (mg/dL)                      | 123.8±18.6               | 145.9±19.2                | 0.005   |
| Maximum (mg/dL)                 | 208.9±34.0               | 233.6±39.3                | 0.095   |
| minimum (mg/dL)                 | 73.3±7.9                 | 96.1±13.6                 | <0.001  |
| SD (mg/dL)                      | 33.5±9.1                 | 35.1±9.2                  | 0.649   |
| CV (mg/dL)                      | 26.9±4.5                 | 24.0±5.1                  | 0.127   |
| GMI (%)                         | 24.0±3.1                 | 27.7±3.2                  | 0.005   |
| TAR (%)                         | 9.9±11.5                 | 18.0±13.1                 | 0.037   |
| TIR (%)                         | 87.7±12.5                | 82.0±13.1                 | 0.179   |
| TBR (%)                         | 2.3±2.6                  | 0                         | <0.001  |
| LBGI (%)                        | 2.5±1.9                  | 0.7±0.5                   | <0.001  |
| MODD (mg/dL)                    | 28.5±12.5                | 31.1±9.2                  | 0.271   |
| AIQR (mg/dL)                    | 29.7±13.7                | 30.8±6.5                  | 0.271   |

Data are mean±SD.
By Student’s t test when variances were equal as determined by an F test, otherwise with Welch’s test.

Unmarked p values, by Mann-Whitney test.

AG, average interstitial glucose: SD, standard deviation: CV, coefficient of variation: GMI, Glucose Management Indicator: TAR, Time above range (>180 mg/dL): TIR, Time in range (70-180 mg/dL): TBR, Time below range (<70 mg/dL): LBGI, low blood glucose index: MODD, mean of daily difference of blood glucose: AIQR, average interquartile range.

Figures

Figure 1

Correlation between average IQR and TIR in patients of the diabetic group. Average IQR correlated negatively with TIR ($r = -0.840$, $p < 0.001$). IQR (interquartile range): TIR (time-in-range) (70-180 mg/dL).
Figure 2

Comparison of TIR by average IQR. (a) Note the significant difference in TIR when AIQR cutoff was 28.3 mg/dL (p<0.001). (b) Note the significant difference in TIR when the AIQR cutoff was 22.9 mg/dL (p=0.001). Data are mean ± standard deviation. IQR (interquartile range): TIR (time-in-range) (70-180 mg/dL).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- sfigure1.jpg
- sfigure2.jpg